Physician profile
David H Geller
NPI 1154350528
$15,812.25
in general payments reported to CMS, 2019-2025
12 companies · $8,970 in 2025
The $8,970 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.87 · 2023: $5,036 · 2024: $1,766 · 2025: $8,970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,799 · Consulting Fee: $3,950 · Travel and Lodging: $1,039 · Food and Beverage: $984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,799.00 |
| Consulting Fee | $3,950.00 |
| Travel and Lodging | $1,039.28 |
| Food and Beverage | $984.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $8,250.09 | 2025 | Skytrofa |
| Pfizer INC. | $6,884.86 | 2023-2025 | |
| Tolmar, INC. | $341.15 | 2025 | Fensolvi |
| Novo Nordisk INC | $125.00 | 2025 | |
| Abbvie INC. | $64.36 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $28.66 | 2025 | |
| Azurity Pharmaceuticals, INC. | $26.00 | 2025 | Triptodur |
| Medtronic, INC. | $25.13 | 2024 | Minimed 780g |
| Ironwood Pharmaceuticals, INC | $24.50 | 2024 | |
| Tandem Diabetes Care, INC. | $21.28 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Zealand Pharma US, INC. | $21.22 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Geller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.